Skye Bioscience, Inc. (SKYE) stock
SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.08+0.16 (+17.52%)
Close on Nov 12, 2026Market cap $38.26MP/E –Yield –
Skye Bioscience ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Skye Bioscience's ebitda for the twelve months ending Jun 30, 2026 was -$51.21M. For fiscal 2025 it was -$57.44M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$57.44M | – |
| FY2024 | Dec 31, 2024 | -$29.89M | – |
| FY2023 | Dec 31, 2023 | -$34.61M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.90M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.50M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.72M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.09M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.06M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.58M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.92M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.12M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$24.69M | – |
See a number that looks wrong?